Phase Forward Inks Multi-Year Agreement with Major Eastern European Pharmaceutical Company Gedeon Richter
October 01 2009 - 8:00AM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced a multi-year agreement with Gedeon Richter Plc., one of
Central-Eastern Europe’s leading pharmaceutical companies with more
than 10,000 employees worldwide. Gedeon Richter plans to adopt
Phase Forward’s Clintrial™ product for its clinical trial data
management activities.
Founded in 1901 and headquartered in Budapest, Hungary, Gedeon
Richter’s world-class organization manufactures and markets generic
pharmaceutical products for the treatment of a variety of therapy
areas including gynecology and cardiology. After completing a
rigorous competitive product review, Gedeon Richter selected Phase
Forward for its comprehensive solutions and the quality of its
services delivery team.
“After an intense review process, Phase Forward’s dedicated
services organization and proven Clintrial product made our
decision a clear one,” said Gy�rgy Németh, medical director, Gedeon
Richter. “We know that we are collaborating with the premier
technology provider for clinical trials – and we look forward to
garnering the benefits inherent in greater drug trial
efficiencies.”
“We’re proud to be working with Gedeon Richter, one of
Central-Eastern Europe’s leading pharmaceutical companies and an
organization dedicated to the kind of drug development work that
will lead to much-needed new and generic therapies,” said Steve
Powell, senior vice president, Phase Forward. “It’s gratifying to
have a company of Gedeon Richter’s reputation choose Phase Forward
after such an extensive, thorough review process.”
About Gedeon Richter Plc.
With a market capitalisation of about US$3.9 billion, Gedeon
Richter had 2008 consolidated sales of about US$1.4 billion. Gedeon
Richter plays the role of a regional multinational company in
Central-Eastern Europe and in the CIS, and has a growing presence
through its commercial subsidiaries in key EU countries, and the
USA. The company has a worldwide presence through its
representative offices and subsidiaries in more than 30 countries.
It has manufacturing sites in Hungary, Russia, Romania, Poland,
India and a R&D biotechnology joint venture in Germany. The
product portfolio of the company covers almost all important
therapeutic areas. With its widely acknowledged steroid chemistry
expertise, the company is a significant player in the
gynaecological field worldwide. 16% of the company’s revenues
results from original drug research and development activity.
Additional information about Gedeon Richter is available at
www.richter.hu.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 290 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to,
among other things, the performance and features of Phase Forward’s
products and services, demand for Phase Forward’s products and
services, future business and operations plans of a Phase Forward
customer, and the ability of Phase Forward’s customers to realize
benefits from the use of Phase Forward’s products and services.
These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are
beyond Phase Forward's control, which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. In particular, the risks and uncertainties include,
among other things, the ability of Phase Forward’s customers to
realize benefits from the use of its products and services, the
possibility that customers’ needs or plans may change over time,
the possibility that the level of demand for Phase Forward’s
products and services may vary, regulatory changes and competition.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise. For additional disclosure regarding
these and other risks faced by Phase Forward, see the disclosure
contained in Phase Forward's public filings with the Securities and
Exchange Commission including, without limitation, its most recent
Annual Report on Form 10-K.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2023 to Jul 2024